Biopharmica pleased with cancer research

LOCAL listed pharmaceutical company Biopharmica has announced successful results from work conducted by the Western Australian Institute for Medical Research (WAIMR) on a cancer gene. According to Biopharmica, the results from a pre-clinical trial conducted at the Royal Perth Hospital campus of WAIMR showed that over 50 per cent of a sample of 70 patients with particular types of cancer, had a fault in a gene identified by research as potentially cancer causing. Biopharmica said the pre-clinical trial directly correlated the presence of a fault in the gene with the development of cancer in humans and developed a highly sensitive test for detecting the cancer gene marker. The company is working in conjunction with the University of WA and WAIMR to commercialise a molecular marker for early and accurate cancer detection.


(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

BNIQ sponsored byECU School of Business and Law


6th-Australian Institute of Management WA20,000
7th-Murdoch University16,584
8th-South Regional TAFE10,549
9th-Central Regional TAFE10,000
49 tertiary education & training providers ranked by total number of students in WA

Number of Employees

BNiQ Disclaimer